These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 29165076)

  • 1. PASylation as a Powerful Technology for Improving the Pharmacokinetic Properties of Biopharmaceuticals.
    Ahmadpour S; Hosseinimehr SJ
    Curr Drug Deliv; 2018; 15(3):331-341. PubMed ID: 29165076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospects of PASylation® for the design of protein and peptide therapeutics with extended half-life and enhanced action.
    Gebauer M; Skerra A
    Bioorg Med Chem; 2018 Jun; 26(10):2882-2887. PubMed ID: 29102080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins.
    Schlapschy M; Binder U; Börger C; Theobald I; Wachinger K; Kisling S; Haller D; Skerra A
    Protein Eng Des Sel; 2013 Aug; 26(8):489-501. PubMed ID: 23754528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficient secretory production of proline/alanine/serine (PAS) biopolymers in Corynebacterium glutamicum yielding a monodisperse biological alternative to polyethylene glycol (PEG).
    Friedrich L; Kikuchi Y; Matsuda Y; Binder U; Skerra A
    Microb Cell Fact; 2022 Oct; 21(1):227. PubMed ID: 36307781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancing bioactivity, physicochemical, and pharmacokinetic properties of a nano-sized, anti-VEGFR2 Adnectin, through PASylation technology.
    Aghaabdollahian S; Ahangari Cohan R; Norouzian D; Davami F; Asadi Karam MR; Torkashvand F; Vaseghi G; Moazzami R; Latif Dizaji S
    Sci Rep; 2019 Feb; 9(1):2978. PubMed ID: 30814652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The polypeptide biophysics of proline/alanine-rich sequences (PAS): Recombinant biopolymers with PEG-like properties.
    Breibeck J; Skerra A
    Biopolymers; 2018 Jan; 109(1):. PubMed ID: 29076532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proline/alanine-rich sequence (PAS) polypeptides as an alternative to PEG precipitants for protein crystallization.
    Schiefner A; Walser R; Gebauer M; Skerra A
    Acta Crystallogr F Struct Biol Commun; 2020 Jul; 76(Pt 7):320-325. PubMed ID: 32627748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved Doxorubicin Encapsulation and Pharmacokinetics of Ferritin-Fusion Protein Nanocarriers Bearing Proline, Serine, and Alanine Elements.
    Falvo E; Tremante E; Arcovito A; Papi M; Elad N; Boffi A; Morea V; Conti G; Toffoli G; Fracasso G; Giacomini P; Ceci P
    Biomacromolecules; 2016 Feb; 17(2):514-22. PubMed ID: 26686226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement of Certolizumab Fab' properties by PASylation technology.
    Mazaheri S; Talebkhan Y; Mahboudi F; Nematollahi L; Cohan RA; Mirabzadeh Ardakani E; Bayat E; Sabzalinejad M; Sardari S; Torkashvand F
    Sci Rep; 2020 Oct; 10(1):18464. PubMed ID: 33116155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PASylation of Murine Leptin Leads to Extended Plasma Half-Life and Enhanced in Vivo Efficacy.
    Morath V; Bolze F; Schlapschy M; Schneider S; Sedlmayer F; Seyfarth K; Klingenspor M; Skerra A
    Mol Pharm; 2015 May; 12(5):1431-42. PubMed ID: 25811325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High contrast tumor imaging with radio-labeled antibody Fab fragments tailored for optimized pharmacokinetics via PASylation.
    Mendler CT; Friedrich L; Laitinen I; Schlapschy M; Schwaiger M; Wester HJ; Skerra A
    MAbs; 2015; 7(1):96-109. PubMed ID: 25484039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PASylation Enhances the Stability, Potency, and Plasma Half-Life of Interferon α-2a: A Molecular Dynamics Simulation.
    Shamloo A; Rostami P; Mahmoudi A
    Biotechnol J; 2020 Aug; 15(8):e1900385. PubMed ID: 32277577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Proline, Alanine, Serine Repeat Sequence for Pharmacokinetic Enhancement of Anti-VEGF Single-Domain Antibody.
    Khodabakhsh F; Salimian M; Mehdizadeh A; Khosravy MS; Vafabakhsh A; Karami E; Cohan RA
    J Pharmacol Exp Ther; 2020 Oct; 375(1):69-75. PubMed ID: 32669367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a novel nano-sized anti-VEGFA nanobody with enhanced physicochemical and pharmacokinetic properties.
    Khodabakhsh F; Norouzian D; Vaziri B; Ahangari Cohan R; Sardari S; Mahboudi F; Behdani M; Mansouri K; Mehdizadeh A
    Artif Cells Nanomed Biotechnol; 2018 Nov; 46(7):1402-1414. PubMed ID: 28841807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Design, Expression and Evaluation of PASylated Human Recombinant Erythropoietin with Enhanced Functional Properties.
    Hedayati MH; Norouzian D; Aminian M; Teimourian S; Ahangari Cohan R; Sardari S; Khorramizadeh MR
    Protein J; 2017 Feb; 36(1):36-48. PubMed ID: 28168382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges and advancements in the pharmacokinetic enhancement of therapeutic proteins.
    Khodabakhsh F; Salimian M; Hedayati MH; Ahangari Cohan R; Norouzian D
    Prep Biochem Biotechnol; 2021; 51(6):519-529. PubMed ID: 33459157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of diet-induced lipodystrophic C57BL/6J mice with long-acting PASylated leptin normalises insulin sensitivity and hepatic steatosis by promoting lipid utilisation.
    Bolze F; Bast A; Mocek S; Morath V; Yuan D; Rink N; Schlapschy M; Zimmermann A; Heikenwalder M; Skerra A; Klingenspor M
    Diabetologia; 2016 Sep; 59(9):2005-12. PubMed ID: 27272237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PASylation improves pharmacokinetic of liposomes and attenuates anti-PEG IgM production: An alternative to PEGylation.
    Zhang Q; Li S; Wu W; Xia X; Zhang J
    Nanomedicine; 2023 Jan; 47():102622. PubMed ID: 36280044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PASylation technology improves recombinant interferon-β1b solubility, stability, and biological activity.
    Zvonova EA; Ershov AV; Ershova OA; Sudomoina MA; Degterev MB; Poroshin GN; Eremeev AV; Karpov AP; Vishnevsky AY; Goldenkova-Pavlova IV; Petrov AV; Ruchko SV; Shuster AM
    Appl Microbiol Biotechnol; 2017 Mar; 101(5):1975-1987. PubMed ID: 27833991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Drug Monitoring of Biopharmaceuticals May Benefit From Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Modeling.
    Passot C; Pouw MF; Mulleman D; Bejan-Angoulvant T; Paintaud G; Dreesen E; Ternant D
    Ther Drug Monit; 2017 Aug; 39(4):322-326. PubMed ID: 28703717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.